Fusion of Therapeutics and Optimal Use of Imaging Technologies!

April 7, 2022 – The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. Imaging Endpoints understands that every data point counts and is critical for successful trial completion, from Phase I through Phase III and FDA submission/approval. Our scientific and radiologic capabilities help assure the optimal use of imaging technologies and data integrity in clinical trials. Learn more about our oncology services at imagingendpoints.com.